Found: 14
Select item for more details and to access through your institution.
Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial.
- Published in:
- Yonago Acta Medica, 2023, v. 66, n. 4, p. 422, doi. 10.33160/yam.2023.11.007
- By:
- Publication type:
- Article
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 251, doi. 10.1159/000528145
- By:
- Publication type:
- Article
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
- Published in:
- PLoS ONE, 2022, v. 17, n. 1, p. 1, doi. 10.1371/journal.pone.0262675
- By:
- Publication type:
- Article
Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma.
- Published in:
- Internal Medicine, 2023, v. 62, n. 12, p. 1771, doi. 10.2169/internalmedicine.9581-22
- By:
- Publication type:
- Article
Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices.
- Published in:
- BMC Gastroenterology, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12876-022-02616-z
- By:
- Publication type:
- Article
Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
- Published in:
- Cancers, 2024, v. 16, n. 7, p. 1328, doi. 10.3390/cancers16071328
- By:
- Publication type:
- Article
Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2023, v. 15, n. 22, p. 5406, doi. 10.3390/cancers15225406
- By:
- Publication type:
- Article
Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma.
- Published in:
- Cancers, 2022, v. 14, n. 2, p. 320, doi. 10.3390/cancers14020320
- By:
- Publication type:
- Article
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 3958, doi. 10.3390/cancers13163958
- By:
- Publication type:
- Article
Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma.
- Published in:
- International Journal of Cancer, 2022, v. 151, n. 12, p. 2278, doi. 10.1002/ijc.34247
- By:
- Publication type:
- Article
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study.
- Published in:
- BMC Gastroenterology, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12876-023-02851-y
- By:
- Publication type:
- Article